PubMed:32198291 13 Projects
Annnotations
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
tok1 | 0-7 | NNP | denotes | Crystal |
tok2 | 8-17 | NN | denotes | structure |
tok3 | 18-20 | IN | denotes | of |
tok4 | 21-30 | NNP | denotes | SARS-CoV- |
tok5 | 30-31 | CD | denotes | 2 |
tok6 | 32-36 | JJ | denotes | main |
tok7 | 37-45 | NN | denotes | protease |
tok8 | 46-54 | VBZ | denotes | provides |
event3 | 46-54 | OCCURRENCE | denotes | provides |
tok9 | 55-56 | DT | denotes | a |
tok10 | 57-62 | NN | denotes | basis |
tok11 | 63-66 | IN | denotes | for |
tok12 | 67-73 | NN | denotes | design |
tok13 | 74-76 | IN | denotes | of |
tok14 | 77-85 | VBN | denotes | improved |
event12 | 77-85 | OCCURRENCE | denotes | improved |
tok15 | 86-97 | JJ | denotes | α-ketoamide |
tok16 | 98-108 | NNS | denotes | inhibitors |
tok17 | 108-109 | . | denotes | . |
tok18 | 110-113 | DT | denotes | The |
tok19 | 114-120 | NNP | denotes | COVID- |
tok20 | 120-122 | CD | denotes | 19 |
tok21 | 123-131 | JJ | denotes | pandemic |
tok22 | 132-138 | VBN | denotes | caused |
event5 | 132-138 | OCCURRENCE | denotes | caused |
tok23 | 139-141 | IN | denotes | by |
lookup1 | 139-141 | country_code | denotes | by |
tok24 | 142-151 | NNP | denotes | SARS-CoV- |
tok25 | 151-152 | CD | denotes | 2 |
tok26 | 153-155 | VBZ | denotes | is |
lookup2 | 153-155 | country_code | denotes | is |
tok27 | 156-157 | DT | denotes | a |
tok28 | 158-164 | JJ | denotes | global |
tok29 | 165-171 | NN | denotes | health |
tok30 | 172-181 | NN | denotes | emergency |
tok31 | 181-182 | . | denotes | . |
tok32 | 183-185 | DT | denotes | An |
tok33 | 186-196 | JJ | denotes | attractive |
tok34 | 197-201 | NN | denotes | drug |
tok35 | 202-208 | NN | denotes | target |
tok36 | 209-214 | IN | denotes | among |
tok37 | 215-228 | NNS | denotes | coronaviruses |
tok38 | 229-231 | VBZ | denotes | is |
lookup3 | 229-231 | country_code | denotes | is |
tok39 | 232-235 | DT | denotes | the |
tok40 | 236-240 | JJ | denotes | main |
tok41 | 241-249 | NN | denotes | protease |
tok42 | 250-251 | ( | denotes | ( |
tok43 | 251-255 | NNP | denotes | Mpro |
tok44 | 255-256 | , | denotes | , |
tok45 | 257-258 | CD | denotes | 3 |
tok46 | 258-263 | NNP | denotes | CLpro |
tok47 | 263-264 | ) | denotes | ) |
tok48 | 264-265 | , | denotes | , |
tok49 | 266-269 | JJ | denotes | due |
tok50 | 270-272 | TO | denotes | to |
lookup4 | 270-272 | country_code | denotes | to |
tok51 | 273-276 | PRP$ | denotes | its |
tok52 | 277-286 | JJ | denotes | essential |
tok53 | 287-291 | NN | denotes | role |
tok54 | 292-294 | IN | denotes | in |
lookup5 | 292-294 | country_code | denotes | in |
tok55 | 295-305 | VBG | denotes | processing |
event10 | 295-305 | OCCURRENCE | denotes | processing |
tok56 | 306-309 | DT | denotes | the |
tok57 | 310-322 | NNS | denotes | polyproteins |
tok58 | 323-327 | WDT | denotes | that |
tok59 | 328-331 | VBP | denotes | are |
tok60 | 332-342 | VBN | denotes | translated |
event8 | 332-342 | OCCURRENCE | denotes | translated |
tok61 | 343-347 | IN | denotes | from |
tok62 | 348-351 | DT | denotes | the |
tok63 | 352-357 | JJ | denotes | viral |
tok64 | 358-361 | NNP | denotes | RNA |
tok65 | 361-362 | . | denotes | . |
tok66 | 363-365 | PRP | denotes | We |
lookup6 | 363-365 | stop | denotes | We |
tok67 | 366-372 | VBP | denotes | report |
event1 | 366-372 | OCCURRENCE | denotes | report |
tok68 | 373-376 | DT | denotes | the |
tok69 | 377-379 | NNP | denotes | X- |
tok70 | 379-382 | NN | denotes | ray |
lookup7 | 379-382 | person_first | denotes | ray |
tok71 | 383-393 | NNS | denotes | structures |
tok72 | 394-396 | IN | denotes | of |
tok73 | 397-400 | DT | denotes | the |
tok74 | 401-411 | JJ | denotes | unliganded |
tok75 | 412-421 | NNP | denotes | SARS-CoV- |
tok76 | 421-422 | CD | denotes | 2 |
tok77 | 423-427 | NNP | denotes | Mpro |
tok78 | 428-431 | CC | denotes | and |
tok79 | 432-435 | PRP$ | denotes | its |
tok80 | 436-443 | JJ | denotes | complex |
tok81 | 444-448 | IN | denotes | with |
tok82 | 449-451 | DT | denotes | an |
lookup8 | 449-451 | country_code | denotes | an |
tok83 | 452-463 | JJ | denotes | α-ketoamide |
tok84 | 464-473 | NN | denotes | inhibitor |
tok85 | 473-474 | . | denotes | . |
tok86 | 475-479 | DT | denotes | This |
lookup9 | 475-479 | time_modifier | denotes | This |
tok87 | 480-483 | VBD | denotes | was |
tok88 | 484-491 | VBN | denotes | derived |
event4 | 484-491 | OCCURRENCE | denotes | derived |
tok89 | 492-496 | IN | denotes | from |
tok90 | 497-498 | DT | denotes | a |
tok91 | 499-509 | RB | denotes | previously |
tok92 | 510-518 | VBN | denotes | designed |
tok93 | 519-528 | NN | denotes | inhibitor |
tok94 | 529-532 | CC | denotes | but |
tok95 | 533-537 | IN | denotes | with |
tok96 | 538-541 | DT | denotes | the |
tok97 | 542-543 | NN | denotes | P |
tok98 | 543-544 | CD | denotes | 3 |
tok99 | 544-545 | : | denotes | - |
tok100 | 545-546 | NN | denotes | P |
tok101 | 546-547 | CD | denotes | 2 |
tok102 | 548-553 | NN | denotes | amide |
tok103 | 554-558 | NN | denotes | bond |
tok104 | 559-571 | VBN | denotes | incorporated |
event6 | 559-571 | OCCURRENCE | denotes | incorporated |
tok105 | 572-576 | IN | denotes | into |
tok106 | 577-578 | DT | denotes | a |
tok107 | 579-587 | NN | denotes | pyridone |
tok108 | 588-592 | NN | denotes | ring |
tok109 | 593-595 | TO | denotes | to |
lookup10 | 593-595 | country_code | denotes | to |
tok110 | 596-603 | VB | denotes | enhance |
event2 | 596-603 | OCCURRENCE | denotes | enhance |
tok111 | 604-607 | DT | denotes | the |
lookup11 | 608-612 | date_unit | denotes | half |
tok112 | 608-617 | NN | denotes | half-life |
tok113 | 618-620 | IN | denotes | of |
tok114 | 621-624 | DT | denotes | the |
tok115 | 625-633 | NN | denotes | compound |
tok116 | 634-636 | IN | denotes | in |
lookup12 | 634-636 | country_code | denotes | in |
tok117 | 637-643 | NN | denotes | plasma |
tok118 | 643-644 | . | denotes | . |
tok119 | 645-650 | VBN | denotes | Based |
event7 | 645-650 | OCCURRENCE | denotes | Based |
tok120 | 651-653 | IN | denotes | on |
tok121 | 654-657 | DT | denotes | the |
tok122 | 658-667 | NN | denotes | structure |
tok123 | 667-668 | , | denotes | , |
tok124 | 669-671 | PRP | denotes | we |
tok125 | 672-681 | VBD | denotes | developed |
event9 | 672-681 | OCCURRENCE | denotes | developed |
tok126 | 682-685 | DT | denotes | the |
tok127 | 686-690 | JJ | denotes | lead |
tok128 | 691-699 | NN | denotes | compound |
tok129 | 700-704 | IN | denotes | into |
tok130 | 705-706 | DT | denotes | a |
tok131 | 707-713 | JJ | denotes | potent |
tok132 | 714-723 | NN | denotes | inhibitor |
tok133 | 724-726 | IN | denotes | of |
tok134 | 727-730 | DT | denotes | the |
tok135 | 731-740 | NNP | denotes | SARS-CoV- |
tok136 | 740-741 | CD | denotes | 2 |
tok137 | 742-746 | NNP | denotes | Mpro |
tok138 | 747-750 | DT | denotes | The |
tok139 | 751-766 | JJ | denotes | pharmacokinetic |
tok140 | 767-783 | NN | denotes | characterization |
tok141 | 784-786 | IN | denotes | of |
tok142 | 787-790 | DT | denotes | the |
tok143 | 791-800 | JJ | denotes | optimized |
tok144 | 801-810 | NN | denotes | inhibitor |
tok145 | 811-818 | VBZ | denotes | reveals |
event11 | 811-818 | OCCURRENCE | denotes | reveals |
tok146 | 819-820 | DT | denotes | a |
tok147 | 821-831 | VBN | denotes | pronounced |
tok148 | 832-836 | NN | denotes | lung |
tok149 | 837-844 | NN | denotes | tropism |
tok150 | 845-848 | CC | denotes | and |
tok151 | 849-860 | NN | denotes | suitability |
tok152 | 861-864 | IN | denotes | for |
tok153 | 865-879 | NN | denotes | administration |
tok154 | 880-882 | IN | denotes | by |
lookup13 | 880-882 | country_code | denotes | by |
tok155 | 883-886 | DT | denotes | the |
tok156 | 887-897 | JJ | denotes | inhalative |
tok157 | 898-903 | NN | denotes | route |
tok158 | 903-904 | . | denotes | . |